IMMVF
vs
S&P 500
IMMVF
S&P 500
Over the past 12 months, IMMVF has underperformed S&P 500, delivering a return of -62% compared to the S&P 500's +27% growth.
Stocks Performance
IMMVF vs S&P 500
Performance Gap
IMMVF vs S&P 500
Performance By Year
IMMVF vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Immunovia AB (publ)
Glance View
Immunovia AB engages in the development of methods for diagnosing complex forms of cancer and autoimmune diseases. The company is headquartered in Lund, Skane and currently employs 65 full-time employees. The company went IPO on 2015-12-01. Tests are based on antibody biomarker microarray analysis using machine-learning and bioinformatics to single-out a set of relevant biomarkers that indicate a certain disease. Thus, forming a disease biomarker signature. Immunovia Dx Laboratories locations in USA and Sweden provides laboratory testing services in two accredited reference laboratories.
